Subscribe Their product offers outstanding solutions to complexcomputer issues yet the process
By Admin
"Their product offers outstanding solutions to complexcomputer issues, yet the process is laid out in a user friendly manner.TuneUp Utilities 2009 is also a great value. COLUMBIA, SC, May 20 (MARKET WIRE) -- BDI Pharma, Inc. (BDI), the preeminent national wholesaler of specialtybiopharmaceutical products, announced today that its Q1 distribution ofWyeth Pharmaceuticals' XYNTHA Antihemophilic Factor (Recombinant) -- themanufacturer's new Plasma-Free and Albumin-Free recombinant factor VIIIproduct -- surpassed the company's projected forecast for that timeperiod. "We could not be more pleased with the market uptake and theready acceptance of XYNTHA we have witnessed since the product's releasein the U.S.," said William Shirey, Executive Vice President of BDI.
"Theantihemophilic marketplace is a highly competitive environment with amyriad of choices for the end-user. The fact that our company's sales forXYNTHA have tracked twenty-two percent (22%) ahead of the resultsforecasted for the first fiscal quarter and continue to pace at an evengreater rate thus far for Q2, reflects BDI's ability to assist its tradepartners with the introduction of new products, the development of brandidentity and the generation of vital market share."XYNTHA Antihemophilic Factor (Recombinant), Plasma/Albumin-Free isapproved by the U.S. Food and Drug Administration (FDA) for the controland prevention of bleeding episodes in patients with hemophilia A(congenital factor VIII deficiency or classic hemophilia) and forsurgical prophylaxis in patients with hemophilia A. XYNTHA'smanufacturing process is albumin-free from start to finish, utilizing aunique synthetic ligand purification process totally free of animalmaterials and a nanofiltration step using a 35 nanometer pore-sizefilter.
XYNTHA is Wyeth's next generation replacement for ReFacto whichexits the U.S. market on May 31, 2009.About BDI Pharma, Inc.Serving the healthcare community since 1995, BDI Pharma, Inc. has built anoutstanding reputation as an industry source for products and service. BDIPharma's market focus is evident in its commitment to specialtybiotherapeutics, chemotherapies, immunologics and hemostatics, includingAlbumin (Human) USP, intravenous immune globulin (IVIG or IGIV),coagulation factors VIII, IX, and VIIa, as well as hyper-immunes,injectables and physician specialty pharmaceuticals. As a recognizedAuthorized Distributor of Record for the products it supplies nationwide,BDI Pharma, Inc. services the entire country and is fully accredited andinsured, fulfilling the licensing requirements in all 50 states.In an arena where access to pertinent clinical data and updatedinformation on market availability is paramount to patient care, BDIPharma, Inc.
defines its customer-centric approach to serving thenation's healthcare community through innovative inventory managementprograms, unparalleled customer service, extensive product knowledge,unique promotional services, emergency availability and urgent needdelivery. The company serves as a source for reference material andmarket data, offering healthcare providers the latest information onproducts, supply and other industry events. BDI Pharma, Inc.'seducational literature and Web site -- -- serve asopen-access resources, contributing to the promotion of thebiopharmaceutical industry and the education of both the healthcarecommunity and general populace.Contact:Brad DavisDirector of MarketingEmail Contact(800)948-9834Copyright 2009, Market Wire, All rights reserved.-0-. NEW YORK (Reuters) - In the eyes of the Federal Reserve, it's the best of both worlds in the bond market That may not last. Crisis in Credit | France | EconomySince March, long-term government bond yields have been rising while short-term yields have remained relatively low, helping banks boost profits by borrowing cheaply and lending at higher rates. At the same time, the rise in Treasury yields has not unduly affected long-term mortgage rates -- a big help for homebuyers in the U.S."As long as mortgage rates remain at their historical lows and the curve remains steep, it is good for both the Fed and the banks," said Rudy Narvas, senior analyst at 4Cast Ltd in New York.
"Right now it seems to be a win/win situation for the Fed."However, this idyllic situation may not persist, and that could pose knotty problems for the Fed.If the economy continues to recover, long-term interest rates may continue to rise, and that may undermine the Fed's efforts to reduce borrowing costs through purchases of Treasuries. But intervening to reduce long-term rates hurts banks, which are benefiting from the ability to borrow cheaply at short rates and lend at higher longer-term rates."Absolutely it creates a dilemma," said Michael Wallace, global market strategist at Action Economics LLC in San Francisco. "You have these two forces going against each other."YIELDS ON THE RISELonger-dated Treasury debt yields, which move opposite to prices, have been rising in recent weeks as investors turned to higher-risk investments such as stocks on expectations of economic improvement. Concerns about a wave of government debt issuance have also weighed on prices.Shorter-dated Treasury yields have remained relatively anchored since December, however.The yield curve, as measured by the difference between yields on two-year Treasury notes and 10-year Treasury notes, widened to about 239 basis points on Wednesday, the largest difference between the two since mid-November.The steepening in the curve is of prime importance to banks as they try to restore their health after the financial crisis devastated the sector and contributed heavily to the economic decline.Banks recorded historic losses in 2008, but many reported improved results in the first quarter due to their renewed ability to borrow money cheaply.